Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

51
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
51
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

59
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
59
Modified-Release Drug Delivery Systems: Classification01:23

Modified-Release Drug Delivery Systems: Classification

93
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
93
Modified-Release Drug Delivery Systems: Influencing Factors01:20

Modified-Release Drug Delivery Systems: Influencing Factors

80
Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage required, and controlling drug release to align with pharmacokinetic and pharmacodynamic needs. The system depends on two key factors: the drug's release from the formulation and its movement through the body to the target site. Unlike conventional dosage forms, where absorption is the limiting step, the rate of drug release is the key determinant in...
80
Bioavailability Enhancement: Drug Permeability Enhancement01:27

Bioavailability Enhancement: Drug Permeability Enhancement

269
Body:After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt...
269
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

77
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
77

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

A specific objective supplemental factor in evaluating acute mountain sickness: ΔHR in combination with SaO2.

Military Medical Research·2015
Same author

Anti-inflammatory effects of 1,25-dihydroxyvitamin D3 in monocytes cultured in serum from patients with type 2 diabetes mellitus and diabetic nephropathy with uremia via Toll-like receptor 4 and nuclear factor-κB p65.

Molecular medicine reports·2015
Same author

Multilocus sequence typing of Streptococcus thermophilus from naturally fermented dairy foods in China and Mongolia.

BMC microbiology·2015
Same author

[Role of EuroSCORE and SinoSCORE in prediction of early postoperative quality of life in patients after coronary artery bypass surgery].

Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences·2015
Same author

Naturally Occurring Stilbenoid TSG Reverses Non-Alcoholic Fatty Liver Diseases via Gut-Liver Axis.

PloS one·2015
Same author

[NT5C2 expression in children with acute leukemia and its clinical significance].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi·2015

関連する実験動画

Updated: Feb 28, 2026

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

657

先進的なデリバリーシステムによる代謝脆弱性の標的化

Wanlin Ye1, Xin Li1, Jocelyn Chandra1

  • 1Department of Pharmaceutical Science, Division of Biomedical Health Sciences, School of Medicine, The Chinese University of Hong Kong, Shenzhen, Guangdong 518172, P.R. China; Department of Biomedical Sciences, Division of Biomedical Health Sciences, School of Medicine, The Chinese University of Hong Kong, Shenzhen, Guangdong 518172, P.R. China.

Trends in pharmacological sciences
|February 26, 2026
PubMed
まとめ

プレシジョン・オミクスは、がん細胞の代謝を標的とすることにより進歩します。新しい代謝調節薬物送達システム（MDDS）は、以前の臨床応用における限界を克服し、標的介入を提供します。

キーワード:
薬物送達システム免疫代謝相互作用代謝調節製剤プレシジョン・オミクス

さらに関連する動画

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.2K
Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier
10:16

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Published on: February 8, 2017

8.1K

関連する実験動画

Last Updated: Feb 28, 2026

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

657
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.2K
Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier
10:16

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Published on: February 8, 2017

8.1K

科学分野:

  • 腫瘍学
  • 代謝工学
  • 薬物送達システム

背景:

  • 代謝調節は、プレシジョン・オミクスにおける重要な戦略です。
  • がん細胞のインビボでの独自の代謝脆弱性を標的とすることは、依然として大きな課題です。
  • 高度なデリバリーシステムは、標的代謝介入を可能にしています。

研究 の 目的:

  • プレシジョン・オミクスにおける代謝調節薬物送達システム（MDDS）の進歩を評価すること。
  • MDDSの臨床応用への道筋を明らかにすること。
  • トランスレーショナルバリアを議論し、代謝に基づく治療薬の開発のための解決策を提案すること。

主な方法:

  • 腫瘍代謝と高度なデリバリーシステムを統合した現在の戦略のレビュー。
  • 代謝の不均一性、生物学的バリア、オフターゲット効果を含む主要なトランスレーショナルバリアの分析。
  • 代謝回路マッピングやAI駆動キャリア設計などの新たなソリューションの探求。

主要な成果:

  • MDDSは、プレシジョン・オミクスにおける標的代謝介入の可能性を示しています。
  • 重大なトランスレーショナルバリアが臨床応用を妨げています。
  • 新たなソリューションがこれらの課題を克服する可能性を提供します。

結論:

  • MDDSは、プレシジョン・オミクスにおける有望なフロンティアを表します。
  • 臨床的成功には、トランスレーショナルバリアへの対処が不可欠です。
  • 代謝に基づく治療薬を進歩させるためには、革新的なアプローチが必要です。